ABSTRACT
The risk of developing invasive fungal infections (IFIs) in the solid organ transplant (SOT) recipient mycosis is linked to the type of transplant, the patient’s overall net state of immunosuppression, use of prophylaxis, and their exposure to fungal pathogens. Having said this, over the past decade, the epidemiology of IFIs in SOT patients has evolved. Modifications in transplant practices (e.g., changes in surgical techniques, conditioning regimens, and new immunosuppressive agents), as well as use of new antifungal drugs contribute to the shift in the numbers and types of IFIs. To say the least, treatment of IFIs in a complex SOT recipient is challenging, and optimal outcome requires prompt diagnosis and consideration of important factors, such as co-infection with immunomodulatory viruses, comorbid conditions, and drug interactions. The management of invasive mycoses within the complex milieu of the SOT recipient is discussed in this chapter.
